Skip Nav Destination
Issues
1 January 2015
-
Cover Image
Cover Image
Hyman, Diamond, and colleagues carried out a prospective, blinded study to quantitatively detect the BRAFV600E mutation in circulating tumor cell-free DNA (cfDNA) from the urine and plasma of patients with Langerhans cell histiocytosis or Erdheim-Chester disease. Urinary cfDNA analysis defined the BRAF genotype of all 30 patients and was 100% concordant with tissue genotypes among treatment-naïve patients. Furthermore, serial urinary cfDNA analyses in patients treated with a BRAF inhibitor or immunomodulatory therapy showed a progressive decrease in BRAFV600E allele burden, consistent with radiographic evidence of disease improvement. Tissue and cfDNA genotyping also identified a previously unreported somatic KRASG12S mutation in a BRAF wild-type patient. These data suggest cfDNA testing as a reliable, noninvasive method to detect BRAFV600E mutations and monitor response to therapy in histiocytic disorders. For details, please see the article by Hyman, Diamond, and colleagues on page 64. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
Issue Sections
In This Issue
In the Spotlight
In Focus
Mini Review
Research Briefs
Real-Time Intravital Imaging Establishes Tumor-Associated Macrophages as the Extraskeletal Target of Bisphosphonate Action in Cancer
Simon Junankar; Gemma Shay; Julie Jurczyluk; Naveid Ali; Jenny Down; Nicholas Pocock; Andrew Parker; Akira Nguyen; Shuting Sun; Boris Kashemirov; Charles E. McKenna; Peter I. Croucher; Alexander Swarbrick; Katherine Weilbaecher; Tri Giang Phan; Michael J. Rogers
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa; Michael Cruise; Ada Tam; Elizabeth C. Wicks; Elizabeth M. Hechenbleikner; Janis M. Taube; Richard L. Blosser; Hongni Fan; Hao Wang; Brandon S. Luber; Ming Zhang; Nickolas Papadopoulos; Kenneth W. Kinzler; Bert Vogelstein; Cynthia L. Sears; Robert A. Anders; Drew M. Pardoll; Franck Housseau
Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
David M. Hyman; Eli L. Diamond; Cecile Rose T. Vibat; Latifa Hassaine; Jason C. Poole; Minal Patel; Veronica R. Holley; Goran Cabrilo; Timothy T. Lu; Maria E. Arcila; Young Rock Chung; Raajit Rampal; Mario E. Lacouture; Neal Rosen; Funda Meric-Bernstam; José Baselga; Razelle Kurzrock; Mark G. Erlander; Filip Janku; Omar Abdel-Wahab
Research Articles
Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer
Michel van Kruchten; Elisabeth G. de Vries; Andor W. Glaudemans; Meta C. van Lanschot; Martijn van Faassen; Ido P. Kema; Myles Brown; Carolien P. Schröder; Erik F. de Vries; Geke A. Hospers
News in Brief
News in Depth
Research Watch
Breast Cancer
Clinical Trials
Colorectal Cancer
Epigenetics
Genomics
Glioma
Immune Evasion
Immunotherapy
Leukemia
Lymphoma
Metastasis
Neuroblastoma
Targeted Therapy
Tumor Suppressors
Tumorigenesis
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.